

Koichiro Watanabe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2747572/publications.pdf>

Version: 2024-02-01

30
papers

379
citations

840776

11
h-index

888059

17
g-index

34
all docs

34
docs citations

34
times ranked

435
citing authors

#	ARTICLE	IF	CITATIONS
1	Relationship of cognitive impairment with depressive symptoms and psychosocial function in patients with major depressive disorder: Cross-sectional analysis of baseline data from PERFORM-J. <i>Journal of Affective Disorders</i> , 2019, 258, 172-178.	4.1	44
2	Is switching antidepressants following early nonresponse more beneficial in acute-phase treatment of depression?: A randomized open-label trial. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 1983-1989.	4.8	38
3	Improvement of psychiatrists' clinical knowledge of the treatment guidelines for schizophrenia and major depressive disorders using the "Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE)" project: A nationwide dissemination, education, and evaluation study. <i>Psychiatry and Clinical Neuroscience</i> , 2019, 73, 642-648.	1.8	35
4	Pharmacological management of depression: Japanese expert consensus. <i>Journal of Affective Disorders</i> , 2020, 266, 626-632.	4.1	30
5	&p'Factors Associated with Non-Remission in Bipolar Disorder: The Multicenter Treatment Survey for Bipolar Disorder in Psychiatric Outpatient Clinics (MUSUBI)&p'. <i>Neuropsychiatric Disease and Treatment</i> , 2020, Volume 16, 881-890.	2.2	21
6	Seven-day shared decision making for outpatients with first episode of mood disorders among university students: A randomized controlled trial. <i>Psychiatry Research</i> , 2019, 281, 112531.	3.3	17
7	Improvements in the degree of understanding the treatment guidelines for schizophrenia and major depressive disorder in a nationwide dissemination and implementation study. <i>Neuropsychopharmacology Reports</i> , 2021, 41, 199-206.	2.3	17
8	Real-world clinical features of and antidepressant prescribing patterns for outpatients with bipolar disorder. <i>BMC Psychiatry</i> , 2020, 20, 555.	2.6	16
9	Factors Associated with Doses of Mood Stabilizers in Real-world Outpatients with Bipolar Disorder. <i>Clinical Psychopharmacology and Neuroscience</i> , 2020, 18, 599-606.	2.0	16
10	Clinical features related to rapid cycling and one-year euthymia in bipolar disorder patients: A multicenter treatment survey for bipolar disorder in psychiatric clinics (MUSUBI). <i>Journal of Psychiatric Research</i> , 2020, 131, 228-234.	3.1	15
11	Relationship of Subjective Cognitive Impairment with Psychosocial Function and Relapse of Depressive Symptoms in Patients with Major Depressive Disorder: Analysis of Longitudinal Data from PERFORM-J. <i>Neuropsychiatric Disease and Treatment</i> , 2021, Volume 17, 945-955.	2.2	14
12	Effect of Sucralfate on Antibiotic Therapy for Helicobacter pylori Infection in Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 4582-4588.	3.2	12
13	Perceptions and impact of bipolar disorder in Japan: results of an Internet survey. <i>Neuropsychiatric Disease and Treatment</i> , 2016, Volume 12, 2981-2987.	2.2	12
14	Estimated model of psychotropic polypharmacy for bipolar disorder: Analysis using patients' and practitioners' parameters in the MUSUBI study. <i>Human Psychopharmacology</i> , 2021, 36, e2764.	1.5	11
15	The experiences of receiving a diagnosis of attention deficit hyperactivity disorder during adulthood in Japan: a qualitative study. <i>BMC Psychiatry</i> , 2020, 20, 373.	2.6	10
16	Prospective Epidemiological Research on Functioning Outcomes Related to Major Depressive Disorder in Japan (PERFORM-J): Protocol for a Prospective Cohort Study. <i>JMIR Research Protocols</i> , 2018, 7, e161.	1.0	10
17	Differences in prescription patterns between real-world outpatients with bipolar I and II disorders in the MUSUBI survey. <i>Asian Journal of Psychiatry</i> , 2022, 67, 102935.	2.0	9
18	Psychiatric outpatients' experiences with shared decision-making: a qualitative descriptive study. <i>Journal of Communication in Healthcare</i> , 2019, 12, 102-111.	1.5	8

#	ARTICLE	IF	CITATIONS
19	Relationship Between Mood Episode and Employment Status of Outpatients with Bipolar Disorder: Retrospective Cohort Study from the Multicenter Treatment Survey for Bipolar Disorder in Psychiatric Clinics (MUSUBI) Project. <i>Neuropsychiatric Disease and Treatment</i> , 2021, Volume 17, 2867-2876.	2.2	6
20	Development and field testing of a decision aid to facilitate shared decision making for adults newly diagnosed with attention-deficit hyperactivity disorder. <i>Health Expectations</i> , 2022, 25, 366-373.	2.6	6
21	Therapeutic Potential of Vortioxetine for Anhedonia-Like Symptoms in Depression: A Post Hoc Analysis of Data from a Clinical Trial Conducted in Japan. <i>Neuropsychiatric Disease and Treatment</i> , 2022, Volume 18, 363-373.	2.2	5
22	Relationship Between Employment Status and Unstable Periods in Outpatients with Bipolar Disorder: A Multicenter Treatment Survey for Bipolar Disorder in Psychiatric Outpatient Clinics (MUSUBI) Study. <i>Neuropsychiatric Disease and Treatment</i> , 2022, Volume 18, 801-809.	2.2	5
23	Real-world clinical predictors of manic/hypomanic episodes among outpatients with bipolar disorder. <i>PLoS ONE</i> , 2021, 16, e0262129.	2.5	5
24	Determinants of three-year clinical outcomes in real-world outpatients with bipolar disorder: The multicenter treatment survey for bipolar disorder in psychiatric outpatient clinics (MUSUBI). <i>Journal of Psychiatric Research</i> , 2022, 151, 683-692.	3.1	5
25	Neurological Toxicity in Metastatic Colorectal Cancer Patients Treated with Modified FOLFOX6 plus Bevacizumab. <i>Japanese Clinical Medicine</i> , 2014, 5, JCM.S15553.	1.9	4
26	Early Improvement with Vortioxetine Predicts Response and Remission: A Post Hoc Analysis of Data from a Clinical Trial Conducted in Japan. <i>Neuropsychiatric Disease and Treatment</i> , 2021, Volume 17, 3735-3741.	2.2	3
27	Factors Associated With Time to Achieve Employment Through Occupational Support Programs in Patients With Mood Disorders: 1 Year Naturalistic Study. <i>Frontiers in Psychiatry</i> , 2021, 12, 617640.	2.6	2
28	Therapeutic Potential of Vortioxetine for Anxious Depression: A Post Hoc Analysis of Data from a Clinical Trial Conducted in Japan. <i>Neuropsychiatric Disease and Treatment</i> , 2021, Volume 17, 3781-3790.	2.2	2
29	Effects of transdiagnostic group treatment for sleep disturbances in adult attention-deficit/hyperactivity disorders and autistic spectrum disorder: a pilot study. <i>Sleep and Biological Rhythms</i> , 2022, 20, 173-180.	1.0	1
30	Improving Employment Through Interpersonal Psychotherapy: A Case Series of Patients With Treatment-Refractory Depression. <i>Frontiers in Psychiatry</i> , 2021, 12, 617305.	2.6	0